Pegylated small molecules

Petites molecules chimiquement modifiees

Abstract

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer obtained from a monodisperse or bimodal water-soluble oligomer composition. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
La présente invention concerne des médicaments à petites molécules chimiquement modifiées par fixation d'un oligomère soluble dans l'eau obtenu à partir d'une composition oligomère soluble dans l'eau monodispersée ou bimodale. Un conjugué de cette invention, lorsqu'il est administré via n'importe quelle voie d'administration, présente une vitesse de traversée de membrane biologique réduite comparée à la vitesse de traversée de la membrane biologique du médicament à petites molécules fixées à l'oligomère soluble dans l'eau.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (1)

    Publication numberPublication dateAssigneeTitle
    WO-03032990-A2April 24, 2003Nektar Therapeutics Al, CorporationPolymer conjugates of opioid antagonists

NO-Patent Citations (1)

    Title
    WANG ET AL., JORUNAL OF NEUROCHEMISTRY, vol. 77, no. 6, 2001, pages 1590 - 1660

Cited By (91)

    Publication numberPublication dateAssigneeTitle
    US-2011071207-A1March 24, 2011Nektar TherapeuticsOligomer-Aryloxy-Substituted Propanamine Conjugates
    EP-2621496-A4September 24, 2014Astrazeneca Ab, Nektar TherapeuticsConjugué cristallin de naloxol-peg
    US-8778898-B2July 15, 2014Nektar TherapeuticsOligomer conjugates of heteropentacyclic nucleosides
    US-9388104-B2July 12, 2016Nektar TherapeuticsChemically modified small molecules
    US-9149539-B1October 06, 2015Astrazeneca Ab, Nektar TherapeuticsCrystalline naloxol-PEG conjugate
    US-9782488-B2October 10, 2017Nektar TherapeuticsOligomer-beta blocker conjugates
    WO-2009089053-A1July 16, 2009Nektar Therapeutics Al, CorporationOligomer-guanidine class conjugates
    US-9168311-B2October 27, 2015Nektar TherapeuticsOligomer-dantrolene conjugates and related compounds
    US-9149538-B2October 06, 2015Nektar TherapeuticsOligomer conjugates of heteropentacyclic nucleosides
    WO-2009105258-A1August 27, 2009Nektar Therapeutics Al, CorporationOligomer conjugates of heteropentacyclic nucleosides
    WO-2009151590-A3February 04, 2010Nektar TherapeuticsProcédés de traitement de métaboliseurs alternatifs de cyp2d6
    US-9226970-B2January 05, 2016Nektar TherapeuticsOligomer modified diaromatic substituted compounds
    US-8440687-B2May 14, 2013Nektar TherapeuticsOligomer-opioid agonist conjugates
    US-8466276-B2June 18, 2013Nektar TherapeuticsOligomer conjugates of heteropentacyclic nucleosides
    US-2013053400-A1February 28, 2013Nektar TherapeuticsOligomer-antihistamine conjugates
    KR-101568428-B1November 11, 2015넥타르 테라퓨틱스올리고머―오피오이드 효능제 컨주게이트
    WO-2009073154-A1June 11, 2009Nektar Therapeutics Al, CorporationComposés tricycliques conjugués à un oligomère
    US-9233165-B2January 12, 2016Nektar TherapeuticsOligomer-aryloxy-substituted propanamine conjugates
    US-9421275-B2August 23, 2016Nektar TherapeuticsOligomer-calcimimetic conjugates and related compunds
    WO-2009099670-A2August 13, 2009Nektar Therapeutics Al, Corporation, Nektar TherapeuticsOligomer-cannabinoid conjugates
    WO-2009067175-A3July 30, 2009Nektar Therapeutics Al Corp, Jennifer Riggs-Sauthier, Wen ZhangConjugués oligomère-dantrolène et composés associés
    EP-3222293-A1September 27, 2017Nektar TherapeuticsConjugués d'agoniste opioïde-oligomère
    US-9512135-B2December 06, 2016Nektar TherapeuticsOligomer-opioid agonist conjugates
    US-9233168-B2January 12, 2016Nektar TherapeuticsOligomer-opioid agonist conjugates
    US-8183376-B2May 22, 2012Nektar TherapeuticsStereoselective reduction of a morphinone
    US-2015174264-A1June 25, 2015Nektar TherapeuticsOligomer-Antihistamine Conjugates
    EP-3228307-A1October 11, 2017Sandoz AgOpioid-antagonisten enthaltende feste dispersion
    US-9233167-B2January 12, 2016Nektar TherapeuticsOligomer-opioid agonist conjugates
    US-9126926-B2September 08, 2015Nektar TherapeuticsOligomer-anticholinergic agent conjugates
    US-9725431-B2August 08, 2017Nektar TherapeuticsOligomer-tricyclic conjugates
    US-8829043-B2September 09, 2014Nektar TherapeuticsOligome-cannabinoid conjugates
    WO-2009151590-A2December 17, 2009Nektar TherapeuticsProcédés de traitement de métaboliseurs alternatifs de cyp2d6
    US-8563726-B2October 22, 2013Nektar TherapeuticsStereoselective reduction of a morphinone
    US-8569343-B2October 29, 2013Nektar TherapeuticsOligomer-opioid agonist conjugates
    EP-2992903-A1March 09, 2016Astrazeneca AB, Nektar TherapeuticsCombinaison d'un conjugué naloxol-peg avec un agoniste opioïde
    US-8536213-B2September 17, 2013Nektar TherapeuticsOligomer-dantrolene conjugates and related compounds
    WO-2010033195-A1March 25, 2010Nektar TherapeuticsPegylated opioids with low potential for abuse
    WO-2009099670-A3January 28, 2010Nektar TherapeuticsConjugués d'oligomère et de cannabinoïde
    US-8722732-B2May 13, 2014Nektar TherapeuticsOligomer-calcimimetic conjugates and related compounds
    US-9827239-B2November 28, 2017Nektar TherapeuticsOligomer-opioid agonist conjugates
    US-2016082117-A1March 24, 2016Jenkem Technology Co.,Ltd.(Tianjin)Low molecular weight polyethylene glycol drug conjugates having improved drug biological activity
    KR-20110058783-AJune 01, 2011넥타르 테라퓨틱스남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
    EP-2010539-A2January 07, 2009Nektar Therapeutics AL, CorporationStereoselective reduction of a morphinone
    WO-2008112261-A1September 18, 2008Nektar Therapeutics Al, CorporationOligomer-anticholinergic agent conjugates
    EP-2010539-A4June 02, 2010Nektar TherapeuticsStereoselektive reduktion eines morphinons
    WO-2008112286-A2September 18, 2008Nektar TherapeuticsDe novo synthesis of conjugates
    US-9132200-B2September 15, 2015Nektar TherapeuticsOligomer-calcium channel blocker conjugates
    WO-2008112257-A1September 18, 2008Nektar TherapeuticsConjugués d'oligomère antihistaminique
    EP-2621496-A1August 07, 2013AstraZeneca AB, Nektar TherapeuticsCrystalline naloxol-peg conjugate
    WO-2008112288-A3December 24, 2008Bo-Liang Deng, Nektar Therapeutics Al Corp, Jennifer Riggs-Sauthier, Timothy Andrew RileyConjugués d'oligomère-agoniste opioïde
    WO-2011011543-A1January 27, 2011Nektar TherapeuticsConjugués oligomères-agonistes opioïdes
    WO-2009120358-A1October 01, 2009Nektar TherapeuticsOligomer-nitrogenous base conjugates
    WO-2008112286-A3November 19, 2009Nektar TherapeuticsSynthèses de novo de conjugués
    WO-2010088340-A1August 05, 2010Nektar TherapeuticsConjugués oligomère-phénothiazine
    KR-101421747-B1July 30, 2014넥타르 테라퓨틱스모르피논의 입체선택적 환원
    US-7786133-B2August 31, 2010Nektar TherapeuticsChemically modified small molecules
    US-9458166-B2October 04, 2016Nektar TherapeuticsOligomer-opioid agonist conjugates
    US-9155797-B2October 13, 2015Nektar TherapeuticsOligomer-cannabinoid conjugates
    WO-2008112287-A1September 18, 2008Nektar TherapeuticsConjugués d'oligomère bêtabloquant
    US-9421204-B2August 23, 2016Nektar TherapeuticsOligomer modified diaromatic substituted compounds
    KR-101561707-B1October 19, 2015넥타르 테라퓨틱스올리고머―항히스타민제 컨주게이트
    US-8349307-B2January 08, 2013Nektar TherapeuticsPolymer conjugates of opioid antagonists
    US-8748648-B2June 10, 2014Nektar TherapeuticsOligomer-calcium channel blocker conjugates
    WO-2009131695-A1October 29, 2009Nektar TherapeuticsConjugués de composés bis-chromonyles oligomères
    JP-2013151563-AAugust 08, 2013Nektar Therapeutics, ネクター セラピューティクスOligomer-opioid agonist conjugate
    US-8952032-B2February 10, 2015Nektar TherapeuticsOligomer-opioid agonist conjugates
    JP-2010521466-AJune 24, 2010ネクター セラピューティックスオリゴマー−オピオイドアゴニスト複合体
    CN-101631569-BNovember 14, 2012尼克塔治疗公司Oligomer-antihistamine conjugates
    EP-2623123-A1August 07, 2013Nektar TherapeuticsConjugués d'agoniste opioïde avec un oligomère
    US-9233169-B2January 12, 2016Nektar TherapeuticsOligomer-bis-chromonyl compound conjugates
    US-9789198-B2October 17, 2017Jenkem Technology Co., Ltd. (Tianjin)Low molecular weight polyethylene glycol drug conjugates having improved drug biological activity
    WO-2011103559-A1August 25, 2011Nektar TherapeuticsComposés diaromatiques substitués modifiés par un oligomère
    WO-2009067175-A2May 28, 2009Nektar Therapeutics Al, CorporationOligomer-dantrolene conjugates and related compounds
    US-9095621-B2August 04, 2015Nektar TherapeuticsOligome-bis-chromonyl compound conjugates
    KR-101660996-B1September 28, 2016넥타르 테라퓨틱스남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
    US-8846021-B2September 30, 2014Oligasis, LlcAcryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
    US-8946285-B2February 03, 2015Nektar TherapeuticsOligomer-opioid agonist conjugates
    JP-2010521462-AJune 24, 2010ネクター セラピューティックスオリゴマー−抗ヒスタミン複合体
    EP-2621496-B1December 16, 2015AstraZeneca AB, Nektar TherapeuticsKristallines naloxol-peg-konjugat
    US-8173666-B2May 08, 2012Nektar TherapeuticsOligomer-opioid agonist conjugates
    US-8067431-B2November 29, 2011Nektar TherapeuticsChemically modified small molecules
    US-8765432-B2July 01, 2014Oligasis, LlcTargeted drug phosphorylcholine polymer conjugates
    EP-2500039-A1September 19, 2012Nektar TherapeuticsOligomer-antihistamine conjugates
    US-9012469-B2April 21, 2015Astrazeneca Ab, Nektar TherapeuticsCrystalline naloxol-peg conjugate
    US-8569380-B2October 29, 2013Nektar TherapeuticsOligomer-tricyclic conjugates
    US-8389759-B2March 05, 2013Nektar TherapeuticsOligomer-anticholinergic agent conjugates
    JP-2009534393-ASeptember 24, 2009ネクター セラピューティックス エイエル,コーポレイションモルヒノンの立体選択的還元
    WO-2009032286-A3January 12, 2012Nektar TherapeuticsConjugués oligomère - bloqueur de canaux calciques
    CN-101466381-BNovember 14, 2012尼克塔治疗公司Stereoselective reduction of a morphinone
    US-2013040961-A1February 14, 2013Nektar TherapeuticsOligomer modified diaromatic substituted compounds
    WO-2010141566-A1December 09, 2010Immunogen, Inc.Procédés de conjugaison